New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For DELL;ADNC;MRK;TSN;CTRP;GDOT;VVUS;NFLX;MCK;MAT;LTM;ALKS;ELN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>
January 28, 2016
07:08 EDTMRKFDA PDUFA Date for Merck's Grazoprevir/Elbasvir is January 28, 2016
January 27, 2016
19:30 EDTNFLXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Facebook (FB), up 11.4%... Mellanox (MLNX), up 6.4%... Paypal (PYPL), up 5%... Crown Castle (CCI), up 2.2%... Citrix (CTXS), up 2.4%... Las Vegas Sands (LVS), up 1%... SanDisk (SNDK), up 1%. ALSO HIGHER: Radius Health (RDUS), up 1.2% after announcing a clinical collaboration with Novartis (NVS)... LinkedIn (LNKD) is up 2.4%, Alphabet (GOOG, GOOGL) is up 2.2% and 2.6%, respectively, Netflix (NFLX) is up 1%, Amazon.com (AMZN) is up 2%, and Twitter (TWTR) is up marginally after Facebook reported quarterly results... MGM Resorts (MGM) is up 2.2% and Wynn Resorts (WYNN) is up 2.2%. DOWN AFTER EARNINGS: ServiceNow (NOW), down 16.5%... eBay (EBAY), down 12.8%... United Rentals (URI), down 9.7%... Juniper Networks (JNPR), down 9.6%... Silicon Graphics (SGI), down 9.1%... Discover Financial (DFS), down 7.4%... InvenSense (INVN), down 6.1%... Core Laboratories (CLB), down 4.3%... Vertex Pharmaceuticals (VRTX), down 1.1%. ALSO LOWER: Incyte (INCY), down 12.8% after announcing that it will halt the Phase 2 sub-study of ruxolitinib or placebo in combination with regorafenib after a planned interim analysis of the high CRP subgroup demonstrated that ruxolitinib plus regorafenib did not show a sufficient level of efficacy to warrant continuation.
18:00 EDTNFLXFacebook executives pleased with China growth, hazy on Oculus launch
Speaking on the company's fourth quarter earnings conference call, Facebook (FB) Chief Executive Officer Mark Zuckerberg highlighted the company's more than 2.5M active advertisers as well as the growth of its Messenger and WhatsApp services, which have expanded to 800M and nearly 1B monthly users, respectively. More services will be coming soon to Messenger, Zuckerberg promised, including airline integration. The CEO noted he is "pleased" with initial consumer reaction to Samsung's (SSNLF) Gear VR virtual reality headset, though commentary on pre-orders for Facebook's own Oculus Rift device was notably light, with Zuckerberg saying only that the Oculus launch is "shaping up to be a big moment for the gaming community." Meanwhile, Chief Operating Officer Sheryl Sandberg said the company is pleased with the growth its seeing in emerging markets, including China, where businesses are using Facebook to reach customers internationally. The commentary comes in contrast to the downbeat macro view voiced during Apple's (AAPL) conference call Tuesday night. Globally, 98 of the quarter's top 100 Facebook advertisers also chose to market on Instagram, Sandberg said, adding that as businesses realize they need to catch up to consumer shifts towards mobile, she foresees a "big" opportunity to continue growing advertiser count. ANALYST TAKE: Piper Jaffray analyst Gene Munster issued a post-earnings note on Facebook, reiterating his Overweight rating and $155 price target on the social network giant in the wake of its strong beat. PRICE ACTION: Shares of Facebook have surged 12.8% to $106.60 in after-hours trading. Other members of the FANG stock grouping are also moving higher, with Amazon (AMZN), Netflix (NFLX) and Alphabet (GOOG) rising a respective 2.3%, 2.25% and 2.6%.
16:18 EDTMCKMcKesson sees FY17 adjusted EPS to grow 7%--12% excluding items
McKesson expects growth in adjusted EPS for FY17 to be between 3% and 8%, as reported, and between 7% and 12%, excluding 48c of gains on the disposition of two businesses and favorable discrete tax items in FY16.
16:17 EDTMCKMcKesson backs FY16 adjusted EPS $12.60-$12.90, consensus $12.77
Subscribe for More Information
16:16 EDTMCKMcKesson reports Q3 adjusted EPS $3.18, consensus $3.13
Reports Q3 revenue $47.9B, consensus $48.8B.
16:01 EDTNFLXOptions Update; January 28, 2016
iPath S&P 500 VIX Short-Term Futures up 1.02 to 26.01. Option volume leaders: AAPL FB BAC NFLX FCX BABA AA X VZ BA T
14:34 EDTMCKNotable companies reporting after market close
Notable companies reporting after the market close, with earnings consensus, include Facebook (FB), consensus 68c... Qualcomm (QCOM), consensus 90c... Texas Instruments (TXN), consensus 69c... McKesson (MCK), consensus $3.13... PayPal (PYPL), consensus 35c... Las Vegas Sands (LVS), consensus 65c... eBay (EBAY), consensus 50c... Crown Castle (CCI), consensus $1.10... Vertex (VRTX), consensus 17c... Discover (DFS), consensus $1.30... SanDisk (SNDK), consensus 89c... ServiceNow (NOW), consensus 8c... Lam Research (LRCX), consensus $1.43... Citrix Systems (CTXS), consensus $1.19... Hologic (HOLX), consensus 42c... Juniper (JNPR), consensus 59c... Cavium (CAVM), consensus 28c... Cirrus Logic (CRUS), consensus 81c.
12:27 EDTNFLXIndonesia telecom blocks Netflix access, WSJ says
Indonesia's state-owned PT Telekomunikasi Indonesia, or Telkom, blocked access to Netflix in the country, the Wall Street Journal reports. Telkom said it blocked access to the streaming service after it determined it didn't have a permit to operate as a content provider in Indonesia, the report says. It added that it objected to some of Netflix's available content, including what it said was violent and adult content, the report says. Reference Link
12:19 EDTMRKPiper Jaffray biopharma analyst holds an analyst/industry conference call
Subscribe for More Information
11:07 EDTMRKGilead sinks as Attorney General probes pricing strategy
Shares of drugmaker Gilead (GILD) are underperforming after Massachusetts Attorney General Maura Healey warned that her office may bring an unfair commercial conduct complaint against it related to the pricing for its Hepatitis C virus treatments Sovaldi and Harvoni. UNFAIR PRICING: Healey, in a letter addressed to Gilead CEO John Martin dated January 22 that has just been made public, said that her office is considering whether Gilead's pricing strategy for Sovaldi and Harvoni may constitute an "unfair trade practice" in violation of Massachusetts law. "Because Gilead's drugs offer a cure for a serious and life-threatening infectious disease, pricing the treatment in a manner that effectively allows HCV to continue spreading through vulnerable populations, as opposed to eradicating the disease altogether, results in massive public harm," Healey stated in her letter to Martin. Healey, who urged Gilead to adjust its pricing strategy, noted that the company has invoked the high cost and risk associated with research and development as a justification for its prices, but she said that Gilead quickly recouped its outlay to acquire Pharmasset by selling "$12.4B worth of HCV medication in the first year alone" after its deal. The AG, who said that Sovaldi costs $1,000 per pill in the U.S. but only $10 per pill in Egypt and about $4 per pill in India, contends that American taxpayers "have been footing the bill for Gilead's record profits." FREQUENT TARGET: The pricing of Gilead's hep C treatments have been the focus of significant criticism and political rhetoric in the past. In December, Senate Finance Committee Ranking Member Ron Wyden and senior committee member Chuck Grassley released the results of an 18-month investigation into the pricing and marketing of Sovaldi and Harvoni. The company "pursued a marketing strategy and final wholesale price of Sovaldi - $1,000 per pill, or $84,000 for a single course of treatment - that it believed would maximize revenue," and "fostering broad, affordable access was not a key consideration in the process of setting the wholesale prices," the senators wrote. Members of the Affordable Drug Pricing Task Force, who held a press conference last November to announce "meaningful action" to combat the "skyrocketing" costs of pharmaceuticals, specifically took aim at Sovaldi. During her campaigning efforts, presidential candidate Hillary Clinton has repeatedly decried the "outrageous" prices of specialty drugs. OTHERS TO WATCH: AbbVie (ABBV), Merck (MRK) and Johnson & Johnson (JNJ) also market or are at work on therapies for hepatitis C. PRICE ACTION: In morning trading, Gilead slid 2% to $90.35.
11:06 EDTNFLXStocks with call strike movement; NFLX COP
Netflix (NFLX) April 105 call option implied volatility increased 5% to 55, ConocoPhillips (COP) May 20 call option implied volatility increased 1% to 46 according to iVolatility.
10:18 EDTMATMattel and Disney Consumer Products announce renewed agreement
Subscribe for More Information
10:00 EDTMRKOn The Fly: Analyst Downgrade Summary
Today's noteworthy downgrades include: BG Group (BRGYY) downgraded to Neutral from Outperform at Credit Suisse... Bed Bath & Beyond (BBBY) downgraded to Sell from Neutral at Citi... Bill Barrett (BBG) downgraded to Neutral from Buy at Ladenburg... Brown & Brown (BRO) downgraded to Underweight at Morgan Stanley... Buffalo Wild Wings (BWLD) downgraded to Neutral from Buy at BTIG... Canadian National (CNI) downgraded to Market Perform from Outperform at Raymond James... DreamWorks (DWA) downgraded to Sell from Hold at Topeka... FirstMerit (FMER) downgraded at RBC Capital... Gentex (GNTX) downgraded to Neutral from Outperform at Baird... Haverty Furniture (HVT) downgraded to Sector Weight from Overweight at KeyBanc... Hercules Technology (HTGC) downgraded to Neutral from Buy at Compass Point... Horizon Technology (HRZN) downgraded to Market Perform from Outperform at Raymond James... Installed Building downgraded to Sector Weight from Overweight at KeyBanc... Jarden (JAH) downgraded to Neutral from Buy at Citi... K+S (KPLUF) downgraded to Sell from Hold at Berenberg... La-Z-Boy (LZB) downgraded at BB&T... Legacy Reserves (LGCY) downgraded to Market Perform from Outperform at FBR Capital... Medivation (MDVN) downgraded to Hold from Buy at Canaccord... Merck (MRK) downgraded to Neutral from Buy at BofA/Merrill... Metaldyne Performance (MPG) downgraded to Neutral from Outperform at Baird... Pier 1 Imports (PIR) downgraded to Sector Weight from Overweight at KeyBanc... Priceline (PCLN) downgraded to Neutral from Buy at Goldman... Profire Energy (PFIE) downgraded to Neutral from Buy at Chardan... Regeneron (REGN) downgraded to Hold at Canaccord... Starwood (HOT) downgraded to Underperform from Outperform at CLSA... Swiss Re (SSREY) downgraded to Equal Weight from Overweight at Morgan Stanley... TSYS (TSS) downgraded to Equal-Weight from Overweight at First Analysis... Talmer Bancorp (TLMR) downgraded to Sector Perform from Outperform at RBC Capital... TopBuild (BLD) downgraded to Sector Weight from Overweight at KeyBanc... TripAdvisor (TRIP) downgraded to Sell from Neutral at Goldman... VMware (VMW) downgraded to Hold from Buy at Summit Research... W.R. Grace (GRA) downgraded to Buy from Conviction Buy at Goldman... WEC Energy (WEC) downgraded to Neutral from Conviction Buy at Goldman... Welltower (HCN) downgraded to Underperform from Market Perform at BMO Capital... Yamana Gold (AUY) downgraded to Neutral from Overweight at JPMorgan.
09:32 EDTNFLX, MRKActive equity options trading on open
Active equity options trading on open: AAPL FB AMZN AAL BAC PCLN NFLX MRK GOOG
09:04 EDTNFLXNetflix could become stronger in a recession, says MKM Partners
MKM Partners analyst Rob Sanderson believes a recession would likely accelerate cord-cutting, which could improve Netflix's competitive position, and he recommends using any near-term weakness in the streaming service provider's shares to build positions. Sanderson, who calls the company's momentum in international markets "outstanding" and think Netflix's margins will be higher than incumbent media players at scale, maintains a Buy rating and $145 price target on Netflix shares.
08:36 EDTMRKMerck downgraded to Neutral on lack of catalysts at BofA/Merrill
Subscribe for More Information
08:31 EDTMRKMerck says FDA accepts for review BLA for investigational antitoxin
Subscribe for More Information
08:29 EDTMRKMerck downgraded to Neutral from Buy at BofA/Merrill
06:10 EDTNFLXAmazon beats Netflix at Sundance deals, NY Post reports
Subscribe for More Information
<< 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use